Anika Therapeutics
$20.81
13
-$0.19-0.9% Friday 20:00
-$0.18-0.86%Friday 23:59After hours
Statistics
Day High
20.84
Day Low
20.8
52W High
22.88
52W Low
8.37
Volume
3,456
Avg. Volume
-
Mkt Cap
278.5M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.26
-0.04
0.19
0.42
Expected EPS
0.235
Actual EPS
N/A
Financials
-9.42%Profit Margin
Unprofitable115.53MRevenue
-10.88MNet Income
Analyst Ratings
21.00Average Price Target
The highest estimate is 21.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ANIK. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Zimmer Biomet
ZBH
Mkt Cap19.25B
Stryker
SYK
Mkt Cap126.84B
Medtronic
MDT
Mkt Cap116.77B
Johnson & Johnson
JNJ
Mkt Cap645.95B
Boston Scientific
BSX
Mkt Cap67.88B
Integra Lifesciences
IART
Mkt Cap1.31B
Baxter International
BAX
Mkt Cap13.51B
Align Technology
ALGN
Mkt Cap11.19B
About
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Show more...
CEO
Stephen D. Griffin
Employees
235
Country
United States
ISIN
US0352551081
WKN
000889120
Listings
0 Comments
Share your thoughts
FAQ
What is Anika Therapeutics stock price today?▼
The current price of ANIK is $20.81 USD — it has decreased by -0.9% in the past 24 hours. Watch Anika Therapeutics stock price performance more closely on the chart.
What is Anika Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Anika Therapeutics stocks are traded under the ticker ANIK.
Is Anika Therapeutics stock price growing?▼
ANIK stock has fallen by -1.37% compared to the previous week, the month change is a +3.22% rise, over the last year Anika Therapeutics has showed a +132.77% increase.
What is Anika Therapeutics market cap?▼
Today Anika Therapeutics has the market capitalization of 278.5M
When is the next Anika Therapeutics earnings date?▼
Anika Therapeutics is going to release the next earnings report on October 29, 2026.
What were Anika Therapeutics earnings last quarter?▼
ANIK earnings for the last quarter are 0.42 USD per share, whereas the estimation was -0.08 USD resulting in a +625% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Anika Therapeutics revenue for the last year?▼
Anika Therapeutics revenue for the last year amounts to 115.53M USD.
What is Anika Therapeutics net income for the last year?▼
ANIK net income for the last year is -10.88M USD.
How many employees does Anika Therapeutics have?▼
As of September 06, 2026, the company has 235 employees.
In which sector is Anika Therapeutics located?▼
Anika Therapeutics operates in the Health & Wellness sector.
When did Anika Therapeutics complete a stock split?▼
Anika Therapeutics has not had any recent stock splits.
Where is Anika Therapeutics headquartered?▼
Anika Therapeutics is headquartered in BEDFORD, United States.